The Journal of infectious diseases · 2026
A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ji Jiahong, Jiang Xiaoyi, Liao Xinlei, Du Fengjiao, Wang Guirong, Huang Hairong, Mei Miao, He Yuan, Tan Xu, Javid Babak, Li Hao
Аннотация
BACKGROUND: Tuberculosis (TB) caused by the Mycobacterium tuberculosis complex (MTBC) is the leading cause of death from a single infectious agent worldwide. Current antibiotics fail against drug-resistant strains, highlighting the urgent need for novel therapies. Host-directed therapy (HDT), which enhances host immunity rather than targeting pathogens directly, offers a promising solution.
METHODS: We use the in vitro cells infection assays and in vivo mouse infection model to identify the effects of a monovalent second mitochondria-derived activator of caspase (SMAC) mimetic named BI82 against mycobacterial infections.
RESULTS: We demonstrate that BI82 potently inhibits Mycobacterium bovis growth in macrophages, while exhibiting synergy with rifampicin. BI82 also significantly restricts M. tuberculosis growth in ex vivo whole-blood assays from both tuberculosis patients and healthy donors. BI82 degrades cellular inhibitor of apoptosis protein 1 (cIAP1), promoting infected cell apoptosis as evidenced by elevated cleaved caspase-3 and phosphorylated mixed lineage kinase domain-like levels. In a mouse model, oral BI82 treatment can reduce M. bovis burden in lungs and spleens, alleviate lung lesions, and increase CD3⁺ T cells with elevated CD4/CD8 ratios.
CONCLUSIONS: Our findings reveal that BI82 employs a unique apoptosis-dependent mechanism to exert broad-spectrum activity against mycobacterial infections, positioning it as a promising HDT candidate.
METHODS: We use the in vitro cells infection assays and in vivo mouse infection model to identify the effects of a monovalent second mitochondria-derived activator of caspase (SMAC) mimetic named BI82 against mycobacterial infections.
RESULTS: We demonstrate that BI82 potently inhibits Mycobacterium bovis growth in macrophages, while exhibiting synergy with rifampicin. BI82 also significantly restricts M. tuberculosis growth in ex vivo whole-blood assays from both tuberculosis patients and healthy donors. BI82 degrades cellular inhibitor of apoptosis protein 1 (cIAP1), promoting infected cell apoptosis as evidenced by elevated cleaved caspase-3 and phosphorylated mixed lineage kinase domain-like levels. In a mouse model, oral BI82 treatment can reduce M. bovis burden in lungs and spleens, alleviate lung lesions, and increase CD3⁺ T cells with elevated CD4/CD8 ratios.
CONCLUSIONS: Our findings reveal that BI82 employs a unique apoptosis-dependent mechanism to exert broad-spectrum activity against mycobacterial infections, positioning it as a promising HDT candidate.